Dermatology (drugs A-E)

(Cimzia®, Cosentyx®, Dupixent®, Enbrel®)

DIPLOMAT®

--Select One--
Phone
Fax
Insert Sales Contact Name (if known)

Patient Information

Patient name: _____ DOB: _____
Sex: ☐ Female ☐ Male SSN: _____
Language: _____ Wt: _____ ☐kg ☐lbs Ht: _____☐cm ☐in
Address: _____
Apt/Suite: _____ City: _____ State: Zip: _____
Phone: _____ Alternate: _____
Caregiver name: _____ Relation: _____
Local pharmacy: _____ Phone: _____
Insurance plan: _____ Plan ID: _____
Please fax a copy of front and back of the insurance card(s).

Prescriber + Shipping Information

Prescriber name: _____
NPI: _____
Address: _____
Apt/Suite: _____ City: _____ State: Zip: _____
Contact: _____
Phone: _____ Alternate: _____
Fax: _____
Email: _____
If shipping to prescriber: ☐ First Fill ☐ Always ☐Never

Clinical Information (Please fax all pertinent clinical and lab information)

Diagnosis: ☐ L20.____ (Atopic Dermatitis) ☐ L40.0 (Psoriasis vulgaris/Plaque Psoriasis/Nummular Psoriasis) ☐ L40.8 (Other psoriasis)
☐ L40.9 (Psoriasis, unspecified) ☐ L40.5____ (Psoriatic arthritis) ☐ L73.2 (Hidradenitis Suppurativa) ☐ _____

Diagnosis Date: _____ TB test: ☐ Yes ☐ No Neg. Test Date: _____ HBV: ☐ Yes ☐ No If yes, currently treated: ☐ Yes ☐ No
BSA affected (%): _____ Affected areas: ☐ Palms ☐ Soles ☐ Head ☐ Neck ☐ Genitalia ☐ _____

Prior Therapy ☐ Yes ☐ No	Reason for Discontinuation of Therapy	Approximate Start Date	Approximate End Date

Comorbidities: _____
Concomitant Medications: _____
Allergies: ☐ NKDA ☐ Other: _____

Has the patient received their starter dose(s)/kit? ☐ Yes; Start Date _____ ☐ No

Prescription		Quantity		Refill
☐ **Cimzia®** **(certolizumab)** *Psoriatic Arthritis*	☐ Inject 400 mg subcut at weeks 0, 2 and 4	☐ 6 x 200 mg/mL	☐ PFS Starter Kit ☐ Vials	0
	☐ Inject 200 mg subcut every 2 weeks ☐ Inject 400 mg subcut every 4 weeks	☐ 2 x 200 mg/mL	☐ PFS ☐ Vials	_____
☐ **Cimzia®** **(certolizumab)** *Plaque Psoriasis*	☐ Inject 400 mg subcut every other week	☐ 2 x 200 mg/mL	☐ PFS ☐ Vials	_____
	☐ For some patients < 90 kg: Inject 400 mg subcut at weeks 0, 2, and 4, then 200 mg every 2 weeks	☐ 6 x 200 mg/mL	☐ PFS Starter Kit ☐ Vials	0
	☐ Inject 200 mg subcut every 2 weeks	☐ 2 x 200 mg/mL	☐ PFS ☐ Vials	_____
☐ **Cosentyx®** **(secukinumab)**	☐ Inject 150 mg subcut once weekly at weeks 0, 1, 2 and 3	☐ 4 x 150 mg/mL	☐ Sensoready® Pen ☐ PFS	0
	☐ Inject 300 mg subcut once weekly at weeks 0, 1, 2 and 3	☐ 8 x 150 mg/mL		
	☐ Inject 150 mg subcut on week 4 and every 4 weeks thereafter	☐ 1 x 150 mg/mL	☐ Sensoready® Pen ☐ PFS	_____
	☐ Inject 300 mg subcut on week 4 and every 4 weeks thereafter	☐ 2 x 150 mg/mL		
☐ **Dupixent®** **(dupilumab)**	☐ Inject 600 mg subcut on day 1	☐ 2 x 300 mg/2 mL	PFS	0
	☐ Inject 300 mg subcut at day 15 and every 2 weeks thereafter	☐ 2 x 300 mg/2 mL	PFS	_____
☐ **Enbrel®** **(etanercept)** *Adult*	☐ Inject 50 mg subcut twice a week (72-96 hours apart) for 3 months	8 x 50 mg/mL	☐ SureClick® Autoinjector ☐ Mini™ Cartridge ☐ PFS	2
	☐ Inject 50 mg subcut every week	4 x 50 mg/mL		_____
☐ **Enbrel®** **(etanercept)** *Pediatric (4-17 yrs)*	☐ Inject _____ mg (0.8mg/kg x _____kg subcut every week (≤ 63 kg)	____ x 25 mg/mL	☐ PFS ☐ Vials	_____
	☐ Inject 50 mg subcut every week (> 63 kg)	4 x 50 mg/mL	☐ SureClick® Autoinjector ☐ Mini™ Cartridge ☐ PFS	_____

Humira®, Ilumya™, Orencia®, Otezla®, Siliq™, Simponi®, Simponi Aria®, Stelara®, Taltz®, Tremfya™, Xeljanz® and Xeljanz® XR are listed alphabetically on respective forms

Injection Training Provided by: ☐ Physician's Office ☐ Pharmacy ☐ Other: _____

Per state-specific law, prescriptions will be dispensed as generic, if applicable, unless notated otherwise: _____

Stamp signature not allowed, physician signature required.

Prescriber's Signature: _____ Date: _____

I authorize Diplomat Pharmacy, Inc. and its representatives to act as an agent to initiate and execute the insurance prior authorization process for this prescription and any future fills of the same prescription for the patient listed above. I understand that I can revoke this designation at any time by providing written notice to Diplomat Pharmacy, Inc.

Confidentiality Statement: This message is intended only for the individual or entity to which it is addressed. It may contain information which may be proprietary and confidential. It may also contain privileged, confidential information which is exempt from disclosure under applicable laws, including the Health Insurance Portability and Accountability Act (HIPAA). If you are not the intended recipient, please note that you are strictly prohibited from disseminating or distributing this information (other than to the intended recipient) or copying this information. If you received this communication in error, please notify the sender immediately by calling 810.768.9178 or by emailing compliance@diplomat.is to obtain instructions as to the proper destruction of the transmitted material. Thank you.

Reset Form

Copyright © 2017 by Diplomat Pharmacy Inc. All rights reserved. Diplomat is a registered trademark of Diplomat Pharmacy Inc. 12062018